
Monday, April 14, 2025 8:37:19 AM
Let me help to put things into proper perspective... through my eyes. Keep in mind, we all will see some or all things differently. Please understand, I could be wrong and if I am wrong for taking such risks to believe, then I would blame nobody except myself. I first sold shares of GCAN over .30+ per share years ago when I was awarded shares of GCAN as a dividend. I was given shares of GCAN as a dividend for buying shares of UNGS publicly. They gave me more shares in GCAN in value than what I had originally spent in UNGS at .0001 per share to get the dividend in GCAN. I could not believe that they actually followed through on their promised dividend to give you shares in another publicly trading company that was trading much higher well into the pennies. I bought back into GCAN because I could not believe that it had dropped down to the .000s range while having an OS much lower than your average .000s stock. I have been holding for years and then came this news in 2025 which finally led me to further my beliefs that something was coming:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175610225
The dilution here in GCAN is minimal in my opinion and doesn't bother me... at all. The OS is still just a little over a billion shares. The entire reason why any stock that you, me, or anyone ever can buy is because of dilution. Without any dilution, there would be no Float to exist in any stock, which are shares available for the public to buy. Of course we all want any dilution to be balanced to the point to where there will eventually be a "demand" for shares to exceed the "supply" of shares to where enough shares are absorbed to make the price go up. This is why I still think we are very good here with the dilution from GCAN. With those 106 million extra shares, that is a small amount. I believe they have been absorbed already from looking at the volume history for GCAN:
https://ih.advfn.com/stock-market/USOTC/greater-cannabis-pk-GCAN/historical?_gl=1*1y6kn7x*_gcl_au*MjU2Njk2MTE2LjE3NDE3ODE4NTE.
Don't get me wrong, that's a lot of shares if it was sitting in mines or your account. However, from the company's perspective, that is small. I think there has been a total of 300+ million shares over the past few months of dilution into GCAN and I'm telling you that such is still not bad. It means something is happening towards the growth of the company in my opinion. That is not the case for all stocks out there in the market, but this is what I believe here in GCAN.
I've been in stocks that had dilutive intentions with no regard to smashing shareholders to dilute billions of shares into the share structure. If GCAN had dilutive intentions to smash shareholders, we would have been seeing dilution in much much larger increments and not just 106 million shares and still that would depend on the reason for that dilution too. Usually we would have been seeing billions of shares added if such intentions were negative. Along with the recent SEC filings of the 10-K, 8-K, Form 3, and Form 4, the dilution is an action taken for a positive purpose which is a subliminal hint that something of value is coming into GCAN in my opinion. Aitan Zacharin, the GCAN CEO, is using his company Sapir LLC to acquire the 100 Million shares of GCAN just as he used Sapir LLC as his vehicle to transact owning shares in Connexa Sports Technologies Inc. (Nasdaq: YYAI) which recently signed a Content Creation Agreement with TikTok for the Middle East and North Africa:
https://www.sec.gov/Archives/edgar/data/2002621/000164117225003129/xslF345X05/ownership.xml
https://www.sec.gov/edgar/browse/?CIK=1674440&owner=exclude
https://www.sec.gov/Archives/edgar/data/1674440/000149315224008729/form424b3.htm
https://www.globenewswire.com/news-release/2025/02/24/3031049/0/en/Connexa-Sports-Technologies-Inc-Signs-Content-Creation-Agreement-with-TikTok-for-the-Middle-East-and-North-Africa.html
Also important to note, Aitan Zacharin, the GCAN CEO did a $160 Million merger of his company Core Gaming into the NASDAQ trading as SYTA:
https://www.prnewswire.com/news-releases/siyata-mobile-signs-definitive-agreement-to-merge-with-leading-ai-gaming-developer-core-gaming-302386037.html
I truly do believe that we are in good hands here with Aitan Zacharin, the GCAN CEO.
Two of the stocks that some of us have compared the GCAN here to are TSNP and TWOH with certain thoughts. TSNP had an OS of nearly 4 billion shares and it ran to $1.93 per share. TSNP did not end well because of its dilutive intentions that I don't see existing here in GCAN. I know the market was a different market back then, but the point is that GCAN doesn't have to hit $1.93 per share for many of us to be happy with an OS roughly around 4 times lower than what TSNP's OS was back then. With the TWOH comparisons, something else to note is that TWOH has also had some recent dilution as of late at much higher prices, to the tune of around 150 million shares. Those shares got eaten right up and the price of TWOH sits at a much higher price with a much higher OS than where GCAN sits. The investors there in TWOH know what we hold for the potential of what is coming. I think the investors here in GCAN should have a little more confidence to know what is coming here in GCAN. I have decided to take the risk in both TWOH and GCAN for similar reasons as I had explained in the post below:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176050822
Something else important to note, some have mentioned two other NASDAQ companies that Aitan Zacharin, the GCAN CEO, has recently had a hand in their growth (YYAI:NASDAQ and SYTA:NASDAQ). Please understand, I believe whatever is coming into GCAN will not have anything to do with those two companies. I think something different will be coming into GCAN. I think the point of mentioning them was to show the positive quality and experience from the GCAN CEO and what he is capable of doing and being a part of making happen. Which strongly suggests that he has some huge plans coming for GCAN too.
v/r
Sterling

Exit Strategy & Etiquette Thoughts for a Stock
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128822531
I never give investing advice; only my beliefs for risks in a stock.
Recent GCAN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2025 03:57:40 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 05/06/2025 12:54:51 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 05/05/2025 10:09:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2025 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2025 11:57:51 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/25/2025 11:53:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2025 09:03:35 PM
- MicroCap is Soaring After Announcing Intent to Maximize Shareholder Value • AllPennyStocks.com • 01/02/2025 05:46:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 02:43:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 10:03:45 AM
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM